Medical Gases

Malayaman, S. Nini; Mychaskiw, George; Ehrenwerth, Jan

doi:10.1016/b978-0-323-11237-6.00001-7

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To do that, two different culture strategies were tested, Strategy 2, a combination of batch and fed-batch using a DO-stat feeding, showing the best performance by allowing the obtention of more than 500 mg/L of raw yRBD in the culture broth. This cultivation procedure represents a simple, robust, scalable, and low-cost method since it involves the use of a stirred-tank bioreactor (STBR), a defined basal salt medium with simple carbon sources (glycerol and methanol), and the provision of oxygen exclusively from compressed air, avoiding the use of pure O 2 and its associated risks [67,68]. This affirmation is especially valid when comparing RBD production with other expression hosts such as eukaryotic cells [69,70].…”

Section: Discussionmentioning

confidence: 95%

Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain Using Pichia pastoris in Stirred-Tank Bioreactor

et al. 2023

View full text Add to dashboard Cite

SARS-CoV-2 was identified as the pathogenic agent causing the COVID-19 pandemic. Among the proteins codified by this virus, the Spike protein is one of the most-external and -exposed. A fragment of the Spike protein, named the receptor binding domain (RBD), interacts with the ACE2 receptors of human cells, allowing the entrance of the viruses. RBD has been proposed as an interesting protein for the development of diagnosis tools, treatment, and prevention of the disease. In this work, a method for recombinant RBD production using Pichia pastoris as a cell factory in a stirred-tank bioreactor (SRTB) up to 7 L was developed. Using a basal saline medium with glycerol, methanol, and compressed air in a four-stage procedure, around 500 mg/L of the raw RBD produced by yeasts (yRBD) and 206 mg/L of purified (>95%) RBD were obtained. Thereby, the proposed method represents a feasible, simple, scalable, and inexpensive procedure for the obtention of RBD for diagnosis kits and vaccines’ formulation.

show abstract

Section: Discussionmentioning

confidence: 95%

Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain Using Pichia pastoris in Stirred-Tank Bioreactor

et al. 2023

View full text Add to dashboard Cite

show abstract

“…As the next step, in this article we describe a rational procedure for SARS-CoV2 RBD production scaling up in P. pastoris up to 7 L. To do that, two different culture strategies were tested, showing strategy 2, a combination of batch and fed-batch using a DOstat feeding, the best performance by allowing the obtention of more than 500 mg/L of raw yRBD in the culture broth. This cultivation procedure represents a simple, robust, scalable and low-cost method since it involves the use of a stirred tank bioreactor (STBR), a defined basal salt medium with simple carbon sources (glycerol and methanol) and the provision of oxygen exclusively from compressed air, avoiding the use of pure O2 and its associated risks [65,66]. This affirmation is especially valid when comparing RBD production with other expression hosts such as eukaryotic cells [67,68].…”

Section: Discussionmentioning

confidence: 95%

Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain (RBD) Using Pichia pastoris in Stirred-Tank Bioreactor

Noseda¹,

D’Alessio²,

Santos³

et al. 2023

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 was identified as the pathogenic agent causing the COVID-19 pandemic. Among the proteins codified by this virus, the Spike is one of the most external and exposed. A fragment of the Spike protein, named the Receptor Binding Protein (RBD) interacts with the ACE2 receptors of human cells, allowing the entrance of the viruses. RBD has been proposed as an interesting protein for the development of diagnosis tools, treatment and prevention of the disease. In this work, a method for recombinant RBD production using Pichia pastoris as a cell factory in a Stirred Tank Bioreactor (SRTB) up to 7 L was developed. Using a basal saline medium with glycerol, methanol and compressed air in a four stages procedure, around 500 mg/L of raw yRBD (RBD produced by yeasts) and 206 mg/L of purified (>95%) RBD were obtained. Thereby, the proposed method represents a feasible, simple, scalable and cheap procedure for the obtention of RBD for diagnosis kits and vaccines formulation

show abstract

Human Factors Engineering in Patient Safety

Weinger

Gaba

2014

Anesthesiology

View full text Add to dashboard Cite

Medical Gases

Cited by 3 publications

References 21 publications

Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain Using Pichia pastoris in Stirred-Tank Bioreactor

Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain Using Pichia pastoris in Stirred-Tank Bioreactor

Development of a Cost-Effective Process for the Heterologous Production of SARS-CoV-2 Spike Receptor Binding Domain (RBD) Using Pichia pastoris in Stirred-Tank Bioreactor

Human Factors Engineering in Patient Safety

Contact Info

Product

Resources

About